Takeda reaches new ground Alzheimer’s drug collaboration

Takeda has announced that it has reached new ground in its drug trials collaboration for the treatment of Alzheimer’s.

The “second milestone” means that Evotec has allowed Takeda exclusive rights to a target in Alzheimer’s disease based on identification and validation work. This would lead to a payment of one million Euros, with Evotec stating that it will be entitled further payments depending on whether Takeda selects further targets from Evotec’s ‘target database’.

Aimed at targeting, validating and identifying certain targets with respect to the cause and progression of Alzheimer’s disease, the goal of the four-year collaboration between Evotec and Takeda is to develop small molecule therapeutics.

Dr John Kemp, executive vice president of research and development at Evotec, commented: “We are extremely proud that we have reached our second project milestone with Takeda.

“Over the past three years we have made excellent progress in building substantial expertise and IP around novel Alzheimer’s disease targets. The relationship with Takeda is very productive and we are looking forward to jointly leveraging our innovative Alzheimer’s disease toolbox during the years to come.”

Evotec has received around 20 million euros in payments towards access fees so far, with further milestone payments to be given for later drug discoveries. Payments will also be given depending on the development of compounds acting on selected targets.

© Adfero Ltd